Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2004 Aug;80(946):452–458. doi: 10.1136/pgmj.2003.013912

Long term motor complications of levodopa: clinical features, mechanisms, and management strategies

B Thanvi 1, T Lo 1
PMCID: PMC1743071  PMID: 15299154

Abstract

Levodopa is the most effective symptomatic treatment of Parkinson's disease. However, after an initial period of dramatic benefit, several limitations become apparent including, "dopa resistant" motor symptoms (postural abnormalities, freezing episodes, speech impairment), "dopa resistant" non-motor signs (autonomic dysfunction, mood and cognitive impairment, etc), and/or drug related side effects (especially psychosis, motor fluctuations, and dyskinesias). Motor complications include fluctuations, dyskinesias, and dystonias. They can be very disabling and difficult to treat. Therefore, strategies should ideally be developed to prevent them. Though mechanisms underlying motor complications are only partially understood, recent work has revealed the importance of pulsatile stimulation of postsynaptic dopamine receptors and the disease severity. As a result of intermittent stimulation there occurs a cascade of changes in cell signalling leading to upregulation of the N-methyl-D-aspartate subtype of gamma-aminobutryric acid-ergic neurones. Modified preparations of levodopa (controlled release preparations, liquid levodopa), catecholamine-o-methyltransferase inhibitors, dopamine agonists, amantidine, and various neurosurgical approaches have been used in the prevention and/or treatment of motor complications. Current management of motor complications is less than satisfactory. With better understanding of the pathogenetic mechanisms, it is hoped that future therapeutic strategies will provide a safer and targeted treatment.

Full Text

The Full Text of this article is available as a PDF (184.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agid Y., Ahlskog E., Albanese A., Calne D., Chase T., De Yebenes J., Factor S., Fahn S., Gershanik O., Goetz C. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord. 1999 Nov;14(6):911–913. doi: 10.1002/1531-8257(199911)14:6<911::aid-mds1001>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  2. Allain H., Destée A., Petit H., Patay M., Schück S., Bentué-Ferrer D., Le Cavorzin P. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group. Eur Neurol. 2000;44(1):22–30. doi: 10.1159/000008188. [DOI] [PubMed] [Google Scholar]
  3. Askmark Håkan, Antonov Karolina, Aquilonius Sten-Magnus. The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption--a nation-wide perspective in Sweden. Parkinsonism Relat Disord. 2003 Jun;9(5):271–276. doi: 10.1016/s1353-8020(02)00117-7. [DOI] [PubMed] [Google Scholar]
  4. Barbeau A. The clinical physiology of side effects in long-term L-DOPA therapy. Adv Neurol. 1974;5:347–365. [PubMed] [Google Scholar]
  5. Blanchet P. J., Metman L. V., Mouradian M. M., Chase T. N. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord. 1996 Sep;11(5):580–581. doi: 10.1002/mds.870110516. [DOI] [PubMed] [Google Scholar]
  6. Block G., Liss C., Reines S., Irr J., Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol. 1997;37(1):23–27. doi: 10.1159/000117399. [DOI] [PubMed] [Google Scholar]
  7. Bové J., Marin C., Bonastre M., Tolosa E. Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse. 2002 Dec 15;46(4):251–257. doi: 10.1002/syn.10112. [DOI] [PubMed] [Google Scholar]
  8. Boyce S., Rupniak N. M., Steventon M. J., Iversen S. D. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol. 1990 Oct;13(5):448–458. doi: 10.1097/00002826-199010000-00006. [DOI] [PubMed] [Google Scholar]
  9. Bronte-Stewart Helen. Parkinson's Disease: Surgical Options. Curr Treat Options Neurol. 2003 Mar;5(2):131–147. doi: 10.1007/s11940-003-0004-1. [DOI] [PubMed] [Google Scholar]
  10. Brooks D. J., Sagar H., UK-Irish Entacapone Study Group Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071–1079. doi: 10.1136/jnnp.74.8.1071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. CARLSSON A., LINDQVIST M., MAGNUSSON T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 1957 Nov 30;180(4596):1200–1200. doi: 10.1038/1801200a0. [DOI] [PubMed] [Google Scholar]
  12. Calon Frédéric, Di Paolo Thérèse. Levodopa response motor complications--GABA receptors and preproenkephalin expression in human brain. Parkinsonism Relat Disord. 2002 Sep;8(6):449–454. doi: 10.1016/s1353-8020(02)00029-9. [DOI] [PubMed] [Google Scholar]
  13. Calon Frédéric, Morissette Marc, Rajput Ali H., Hornykiewicz Oleh, Bédard Paul J., Di Paolo Thérèse. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord. 2003 Mar;18(3):241–253. doi: 10.1002/mds.10343. [DOI] [PubMed] [Google Scholar]
  14. Cedarbaum J. M., Hoey M., McDowell F. H. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. J Neurol Neurosurg Psychiatry. 1989 Feb;52(2):207–212. doi: 10.1136/jnnp.52.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chase T. N., Holden E. M., Brody J. A. Levodopa-induced dyskinesias. Comparison in Parkinsonism-dementia and amyotrophic lateral sclerosis. Arch Neurol. 1973 Nov;29(5):328–333. doi: 10.1001/archneur.1973.00490290068008. [DOI] [PubMed] [Google Scholar]
  16. Chase T. N. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs. 1998;55 (Suppl 1):1–9. doi: 10.2165/00003495-199855001-00001. [DOI] [PubMed] [Google Scholar]
  17. Clarke C. E., Boyce S., Sambrook M. A., Crossman A. R. Timing of levodopa therapy: evidence from MPTP-treated primates. Lancet. 1987 Mar 14;1(8533):625–625. doi: 10.1016/s0140-6736(87)90260-1. [DOI] [PubMed] [Google Scholar]
  18. Cotzias G. C., Van Woert M. H., Schiffer L. M. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967 Feb 16;276(7):374–379. doi: 10.1056/NEJM196702162760703. [DOI] [PubMed] [Google Scholar]
  19. Cristina S., Zangaglia R., Mancini F., Martignoni E., Nappi G., Pacchetti Claudio. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin Neuropharmacol. 2003 May-Jun;26(3):146–150. doi: 10.1097/00002826-200305000-00008. [DOI] [PubMed] [Google Scholar]
  20. Crosby N. J., Deane K. H. O., Clarke C. E. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev. 2003;(2):CD003467–CD003467. doi: 10.1002/14651858.CD003467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Djaldetti Ruth, Melamed Eldad. New drugs in the future treatment of Parkinson's disease. J Neurol. 2002 Sep;249 (Suppl 2):II30–II35. doi: 10.1007/s00415-002-1206-2. [DOI] [PubMed] [Google Scholar]
  22. EHRINGER H., HORNYKIEWICZ O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr. 1960 Dec 15;38:1236–1239. doi: 10.1007/BF01485901. [DOI] [PubMed] [Google Scholar]
  23. Fabbrini G., Juncos J., Mouradian M. M., Serrati C., Chase T. N. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol. 1987 Apr;21(4):370–376. doi: 10.1002/ana.410210409. [DOI] [PubMed] [Google Scholar]
  24. Fox Susan H., Henry Brian, Hill Michael, Crossman Alan, Brotchie Jonathan. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord. 2002 Nov;17(6):1180–1187. doi: 10.1002/mds.10289. [DOI] [PubMed] [Google Scholar]
  25. Horstink M. W., Zijlmans J. C., Pasman J. W., Berger H. J., van't Hof M. A. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry. 1990 Mar;53(3):224–226. doi: 10.1136/jnnp.53.3.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Jespersen H. F., Jørgensen H. S., Nakayama H., Reith J., Olsen T. S. Carotid Doppler - costs and need after stroke or TIA. Acta Neurol Scand. 2002 Jan;105(1):1–4. doi: 10.1034/j.1600-0404.2002.0o348.x. [DOI] [PubMed] [Google Scholar]
  27. Kostić V. S., Marinković J., Svetel M., Stefanova E., Przedborski S. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. Eur J Neurol. 2002 Jan;9(1):9–14. doi: 10.1046/j.1468-1331.2002.00346.x. [DOI] [PubMed] [Google Scholar]
  28. Kurth M. C., Tetrud J. W., Irwin I., Lyness W. H., Langston J. W. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology. 1993 May;43(5):1036–1039. doi: 10.1212/wnl.43.5.1036. [DOI] [PubMed] [Google Scholar]
  29. Laitinen L. V. Pallidotomy for Parkinson's disease. Neurosurg Clin N Am. 1995 Jan;6(1):105–112. [PubMed] [Google Scholar]
  30. LeWitt P. A., Nelson M. V., Berchou R. C., Galloway M. P., Kesaree N., Kareti D., Schlick P. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology. 1989 Nov;39(11 Suppl 2):45–59. [PubMed] [Google Scholar]
  31. Maratos Eleni C., Jackson Michael J., Pearce Ronald K. B., Cannizzaro Carla, Jenner Peter. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp Neurol. 2003 Jan;179(1):90–102. doi: 10.1006/exnr.2002.8055. [DOI] [PubMed] [Google Scholar]
  32. Marco Aimee Di, Appiah-Kubi Linda S., Chaudhuri K. Ray. Use of the dopamine agonist cabergoline in the treatment of movement disorders. Expert Opin Pharmacother. 2002 Oct;3(10):1481–1487. doi: 10.1517/14656566.3.10.1481. [DOI] [PubMed] [Google Scholar]
  33. Mones R. J., Elizan T. S., Siegel G. J. Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism. J Neurol Neurosurg Psychiatry. 1971 Dec;34(6):668–673. doi: 10.1136/jnnp.34.6.668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Mouradian M. M., Heuser I. J., Baronti F., Chase T. N. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol. 1990 Jan;27(1):18–23. doi: 10.1002/ana.410270105. [DOI] [PubMed] [Google Scholar]
  35. Narabayashi H., Yokochi F., Nakajima Y. Levodopa-induced dyskinesia and thalamotomy. J Neurol Neurosurg Psychiatry. 1984 Aug;47(8):831–839. doi: 10.1136/jnnp.47.8.831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Nygaard T. G., Marsden C. D., Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology. 1991 Feb;41(2 ):174–181. doi: 10.1212/wnl.41.2_part_1.174. [DOI] [PubMed] [Google Scholar]
  37. Nyholm Dag, Askmark Håkan, Gomes-Trolin Cecilia, Knutson Tina, Lennernäs Hans, Nyström Christer, Aquilonius Sten-Magnus. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol. 2003 May-Jun;26(3):156–163. doi: 10.1097/00002826-200305000-00010. [DOI] [PubMed] [Google Scholar]
  38. Oh J. D., Chase T. N. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids. 2002;23(1-3):133–139. doi: 10.1007/s00726-001-0118-2. [DOI] [PubMed] [Google Scholar]
  39. Oh Justin D., Bibbiani Francesco, Chase Thomas N. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp Neurol. 2002 Oct;177(2):557–564. doi: 10.1006/exnr.2002.8009. [DOI] [PubMed] [Google Scholar]
  40. Olanow C. W., Obeso J. A. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology. 2000;55(11 Suppl 4):S72–S81. [PubMed] [Google Scholar]
  41. Priano L., Albani G., Calderoni S., Baudo S., Lopiano L., Rizzone M., Astolfi V., Cavalli R., Gasco M. R., Fraschini F. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease. Neurol Sci. 2002 Sep;23 (Suppl 2):S99–100. doi: 10.1007/s100720200088. [DOI] [PubMed] [Google Scholar]
  42. Quinn N. Parkinsonism--recognition and differential diagnosis. BMJ. 1995 Feb 18;310(6977):447–452. doi: 10.1136/bmj.310.6977.447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Rascol O., Brooks D. J., Korczyn A. D., De Deyn P. P., Clarke C. E., Lang A. E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000 May 18;342(20):1484–1491. doi: 10.1056/NEJM200005183422004. [DOI] [PubMed] [Google Scholar]
  44. Schneider J. S. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav. 1989 Sep;34(1):193–196. doi: 10.1016/0091-3057(89)90372-9. [DOI] [PubMed] [Google Scholar]
  45. Sommer U., Müller A., Herting B., Cormann K., Kohlert F., Reichmann H. Entacapon zur Therapie der motorischen Fluktuationen bei idiopathischem Parkinson-Syndrom. Nervenarzt. 2002 Aug;73(8):761–764. doi: 10.1007/s00115-002-1354-8. [DOI] [PubMed] [Google Scholar]
  46. Stocchi Fabrizio, Ruggieri Stefano, Vacca Laura, Olanow C. Warren. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain. 2002 Sep;125(Pt 9):2058–2066. doi: 10.1093/brain/awf214. [DOI] [PubMed] [Google Scholar]
  47. Vaamonde J., Ibáez R., Gudín M., Hernández A. Fluctuaciones y disquinesias como complicación precoz de la levodopaterapia en pacientes parkinsonianos graves. Neurologia. 2003 Apr;18(3):162–165. [PubMed] [Google Scholar]
  48. Verhagen Metman L. Recognition and treatment of response fluctuations in Parkinson's disease: review article. Amino Acids. 2002;23(1-3):141–145. doi: 10.1007/s00726-001-0119-1. [DOI] [PubMed] [Google Scholar]
  49. Østergaard Karen, Sunde Niels, Dupont Erik. Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. Mov Disord. 2002 Jul;17(4):693–700. doi: 10.1002/mds.10188. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES